| Literature DB >> 21885537 |
Nele Devoogdt1, Marie-Rose Christiaens, Inge Geraerts, Steven Truijen, Ann Smeets, Karin Leunen, Patrick Neven, Marijke Van Kampen.
Abstract
OBJECTIVE: To determine the preventive effect of manual lymph drainage on the development of lymphoedema related to breast cancer.Entities:
Mesh:
Year: 2011 PMID: 21885537 PMCID: PMC3164214 DOI: 10.1136/bmj.d5326
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Overview of different treatment modalities applied during individual sessions of exercise therapy, with duration of 30 minutes a session, and their purpose and description of method in patients after unilateral axillary lymph node dissection for breast cancer
| Modality | Purpose | Method |
|---|---|---|
| Mobilisation of shoulder | To improve passive and active shoulder mobility | Average 10 minutes per session. Angular passive mobilisation of shoulder (especially anteflexion and abduction) combined with traction/translation to prevent articular problems and impingement |
| Stretching breast muscles | To improve muscle flexibility and passive and active shoulder mobility | Average 10 minutes per session (together with scar tissue massage). Passive and active stretching and transverse strain of major and minor pectoral muscle |
| Scar tissue massage | To improve flexibility of scar tissue | Mobilisation of scar tissue, by gripping scar tissue between thumbs and index fingers and moving hands in opposite direction |
| Exercise schemes | To improve muscle flexibility, endurance, and strength and active shoulder mobility and to stimulate lymphatic transport | Average 10 minutes per session. 10 exercise schemes built steadily and incrementally in difficulty. Each exercise scheme consisted of exercise with proprioceptive neuromuscular facilitation (3×); active stretching of breast muscles (3×15 s); four different exercises—for example, scheme 1: 1) lying supine and both hands on shoulder, perform anteflexion of both shoulders; 2) same, but abduction; 3) same, but circumduction; 4) lying supine, hands crossed, elbows straight and 90° anteflexion of shoulder, perform protraction of both shoulders. Scheme 5: 1) standing, holding stick in both hands on buttock with straight elbows, perform retroflexion of both shoulders; 2) same, but on thighs, perform anteflexion of shoulders; 3) same and 90° anteflexion of shoulder, perform horizontal abduction of affected shoulder; 4) standing, holding stick in both hands at shoulder height, straighten elbows above head. At start of each exercise scheme, exercises were performed 7×, then 10×, then 10× slow and 5× fast, and finally 10× slow and 10× fast. Patients were asked to perform exercises from scheme twice/day at home, as taught during treatment sessions |
Overview of primary and secondary outcome parameters and assessment methods in patients after unilateral axillary lymph node dissection for breast cancer
| Outcome parameter | Measurement method |
|---|---|
| Cumulative incidence of arm lymphoedema, defined as ≥200 mL increase | Arm volume with water displacement method |
| Time to develop arm lymphoedema, defined as ≥200 mL increase | Arm volume with water displacement method |
| Cumulative incidence of arm lymphoedema, defined as ≥2 cm increase at two or more adjacent places | Arm circumferences with measurement device |
| Time to develop arm lymphoedema, defined as ≥2 cm increase at two or more adjacent places | Arm circumferences with measurement device |
| Point prevalence of arm lymphoedema, defined as ≥200 mL increase | Arm volume with water displacement method |
| Point prevalence of arm lymphoedema, defined as ≥2 cm increase at two or more adjacent places | Arm circumferences with measurement device |
| Point prevalence of subjective arm lymphoedema | Author developed questionnaire |
| Increase of arm volume | Arm volume with water displacement method |
| Health related quality of life | SF-36 |

Fig 1 Trial profile of patients with breast cancer undergoing axillary lymph node dissection according to allocation to intervention (guidelines, exercise therapy, and manual lymph drainage) or control (guidelines, exercise therapy)
Characteristics of patients according to treatments to prevent development of lymphoedema related to breast cancer. Figures are numbers (percentage) of patients unless specified otherwise
| Intervention (guidelines, exercise, manual drainage; n=77) | Control (guidelines, exercise; n=81) | |
|---|---|---|
| Men | 1 (1) | 1 (1) |
| Women | 78 (99) | 80 (99) |
| Mean (SD) age (years) | 55.8 (12.5) | 54.5 (11.1) |
| Mean (SD) BMI | 26.6 (5.4) | 26.2 (5.4) |
| Median (IQR) increase in arm volume before start of allocated treatment (mL) | 8 (−34-56) | 8 (−16-64) |
| Mean (SD) interval between surgery and start of allocated treatment (days) | 40 (8) | 34 (12) |
| Mean (SD) No of sessions: | ||
| Exercise therapy | 28 (6) | 28 (8) |
| Manual lymph drainage | 34 (7) | 0 |
| Mean (SD) No of lymph nodes | 19 (6) | 18 (6) |
| Type of breast surgery: | ||
| Mastectomy | 52 (66) | 56 (69) |
| Breast conserving | 27 (34) | 25 (31) |
| Surgery on dominant side | 47 (60) | 44 (54) |
| Level of axillary surgery: | ||
| I | 2 (3) | 0 (0) |
| I-II | 43 (54) | 54 (67) |
| I-III | 34 (43) | 27 (33) |
| Tumour size : | ||
| pT0 | 1 (1) | 0 (0) |
| pT1 | 21 (27) | 26 (32) |
| pT2 | 38 (48) | 39 (48) |
| pT3 | 13 (17) | 12 (15) |
| pT4 | 6 (8) | 4 (5) |
| Lymph node stage: | ||
| pN0 | 23 (29) | 25 (31) |
| pN1 | 36 (46) | 39 (48) |
| pN2 | 11 (14) | 9 (11) |
| pN3 | 9 (11) | 8 (10) |
| Radiotherapy, IMC and medial supraclavicular | 69 (87) | 67 (83) |
| Radiotherapy, axilla | 8 (10) | 5 (6) |
| Chemotherapy | 50 (63) | 58 (72) |
| Neo-adjuvant chemotherapy | 14 (18) | 14 (17) |
| Trastuzumab | 14 (18) | 7 (9) |
| Endocrine treatment | 55 (70) | 66 (82) |
BMI=body mass index; IQR=interquartile range; IMC=internal mammary chain.
Comparison of cumulative incidence and point prevalence of arm lymphoedema after surgery for breast cancer at 3, 6, and 12 months for different definitions according to treatments to prevent lymphoedema
| Definition of lymphoedema | Intervention (guidelines, exercise, manual drainage; n=77) | Control (guidelines, exercise; n=81) | Odds ratio (95% CI) | P value* |
|---|---|---|---|---|
| Cumulative incidence, ≥200 mL increase: | ||||
| At 3 months | 8 (10%) | 6 (7%) | 1.4 (0.5 to 4.4) | 0.51 |
| At 6 months | 11 (14%) | 12 (15%) | 0.9 (0.4 to 2.3) | 0.93 |
| At 12 months† | 18 (24%) | 15 (19%) | 1.3 (0.6 to 2.9) | 0.45 |
| Cumulative incidence, ≥2 cm increase: | ||||
| At 3 months | 8 (10%) | 6 (7%) | 1.4 (0.5 to 4.4) | 0.51 |
| At 6 months | 12 (16%) | 11 (14%) | 1.2 (0.5 to 2.8) | 0.72 |
| At 12 months† | 20 (27%) | 16 (20%) | 1.4 (0.7 to 3.0) | 0.35 |
| Point prevalence, ≥200 mL increase: | ||||
| At 3 months | 5 (7%) | 3 (4%) | 1.8 (0.4 to 7.8) | 0.43 |
| At 6 months | 4 (5%) | 8 (10%) | 0.5 (0.1 to 1.7) | 0.28 |
| At 12 months† | 9 (12%) | 8 (10%) | 1.2 (0.4 to 3.3) | 0.71 |
| Point prevalence, ≥2 cm increase: | ||||
| At 3 months | 5 (7%) | 4 (5%) | 1.3 (0.3 to 5.2) | 0.67 |
| At 6 months | 6 (8%) | 8 (10%) | 0.8 (0.3 to 2.3) | 0.65 |
| At 12 months† | 11 (15%) | 7 (9%) | 1.8 (0.6 to 4.8) | 0.27 |
| Point prevalence, subjective: | ||||
| At 3 months | 14 (18%) | 9 (11%) | 1.8 (0.7 to 4.4) | 0.21 |
| At 6 months | 12 (16%) | 8 (10%) | 1.7 (0.6 to 4.4) | 0.28 |
| At 12 months† | 18 (24%) | 14 (18%) | 1.5 (0.7 to 3.2) | 0.34 |
*For logistic regression analysis.
†75 in intervention group, 79 in control group.

Fig 2 Time to develop lymphoedema after axillary lymph node dissection for breast cancer in 160 patients for two definitions of lymphoedema: increase ≥200 mL in volume or increase ≥2 cm in circumference at two adjacent points
Comparison of changes in difference in arm volume between affected and healthy arm compared with difference in volume before surgery for breast cancer and comparison of mental and physical health related quality of life (secondary outcomes) between groups at each follow-up according to treatments to prevent lymphoedema
| Time after surgery | Intervention (guidelines, exercise, manual drainage; n=77) | Control (guidelines, exercise; n=81) | P value* |
|---|---|---|---|
| Change in difference in arm volume (mL): | |||
| At 3 months | 29 (82) | 18 (101) | 0.69 |
| At 6 months | 58 (104) | 31 (114) | 0.42 |
| At 12 months† | 34 (158) | 45 (111) | 0.97 |
| Quality of life: | |||
| Mental health (maximum score 100): | |||
| At 3 months | 72 (34) | 69 (38) | 0.70 |
| At 6 months | 74 (42) | 68 (33) | 0.59 |
| At 12 months† | 79 (36) | 81 (32) | 0.74 |
| Physical health (maximum score 100): | |||
| At 3 months | 56 (27) | 56 (38) | 0.54 |
| At 6 months | 63 (40) | 58 (36) | 0.81 |
| At 12 months† | 74 (37) | 77 (35) | 0.48 |
*For Mann-Whitney U test.
†75 in intervention group, 79 in control group.

Fig 3 Change in difference in arm volume between affected and healthy side compared with preoperative difference 12 months after surgery for breast cancer. Vertical line corresponds to cut-off value for diagnosis of lymphoedema (≥200 mL increase)

Fig 4 Maximum increase in difference in arm circumference between affected and healthy side at two or more adjacent measurement points compared with preoperative difference 12 months after surgery for breast cancer. Vertical line corresponds to cut-off value for diagnosis of lymphoedema (≥2 cm increase at two or more adjacent measurement points)